16 Aug Monkeypox Update: Switch to JYNNEOS Intradermal Strategy
Posted at 16:25h
in Mpox
Monkeypox Update: Switch to JYNNEOS Intradermal Strategy
Due to a shortage of doses, the PDPH recommends that providers switch to intradermal vaccination as soon as possible.
Intradermal administration involves injecting the vaccine superficially between the epidermis and the hypodermis layers of the skin, typically of the inner side of the forearm.
Intradermal JYNNEOS administration can be considered for most adults ages 18 years and older. Exceptions include people with a history of developing keloid scars. It is also recommended that clinicians observe patients after vaccination to monitor for the occurrence of immediate adverse reactions; 15 minutes is suggested for most patients, 30 minutes for persons with a history of anaphylaxis to gentamicin, ciprofloxacin, chicken, or egg protein.
- View the CDC recommendations on administration.
- View the CDC’s Intradermal Vaccine Preparation and Administration Summary.
Vaccine Schedule and Dosing Regimens
While JYNNEOS dose availability is currently limited, the recommendation is for providers to begin with a single shot. When there is enough vaccine to administer two shots (a complete dose), the recommended dosing interval between the first and second dose of JYNNEOS vaccine for both the standard (subcutaneous administration) and the alternative (intradermal administration) dosing regimens is 28 days for both.
For further questions, email vaccines@phila.gov.